1 Rare Disease With an Array of Drugshttp://www.fool.com/investing/general/2012/10/02/1-rare-disease-with-an-array-of-drugs.aspx Keith Speights
October 2, 2012
French drugmaker Sanofi (NYSE: SNY ) announced good news from its recent phase 3 trial of eliglustat tartrate, a drug targeting Gaucher disease. The trial met its primary endpoint of statistically significant improvement in spleen size at nine months for patients taking the drug. No safety concerns were raised during the study.
Sanofi already maintains a significant presence in the market for Gaucher disease with its Cerezyme injection. Cerezyme is considered the standard of care for patients with type 1 of the disease.
However, Shire PLC (Nasdaq: SHPG ) has made inroads with its Vpriv drug. Shire trumpeted clinical data in June that showed that patients receiving Vpriv experienced better lumbar spine bone mineral density than patients taking Cerezyme. The FDA granted orphan status to Vpriv in 2009, with the European Commission following in 2010. The drug i